A groundbreaking study is reshaping how doctors choose sedatives during emergency airway management, potentially impacting the lives of critically ill patients.
When a patient's breathing is compromised in an emergency, doctors must quickly insert a breathing tube, a procedure known as tracheal intubation. The choice of sedative used during this critical process has long been debated. A recent randomized trial published in the New England Journal of Medicine suggests a significant shift in this practice.
The study, called the Randomized Trial of Sedative Choice for Intubation (RSI), is the first large-scale, multi-center trial to directly compare the effects of two commonly used sedatives: ketamine and etomidate. The results are compelling.
The RSI trial, led by Dr. Jonathan Casey and Dr. Matthew Semler from Vanderbilt University Medical Center, involved 2,365 patients across 14 emergency departments and intensive care units in the U.S. The primary finding? Etomidate proved to be a safer choice. It did not increase the risk of death, and, crucially, it significantly reduced the risk of dangerously low blood pressure (hypotension) during the procedure, a risk more frequently associated with ketamine.
But here's where it gets controversial... Historically, etomidate was the more common sedative, but concerns arose that it might impair cortisol production, potentially increasing the risk of death after intubation. This led some countries to remove etomidate from the market. Ketamine then gained popularity.
"These two medicines, ketamine and etomidate, were approved by the FDA (Food and Drug Administration) before I was born," said Semler. "For more than 40 years, they've been administered to millions of critically ill adults each year. Yet, our RSI trial is the first large, multicenter trial to examine which of the two medicines results in best outcomes for patients."
The RSI trial's findings challenge long-held assumptions. The study revealed that ketamine can cause severely low blood pressure during intubation. This is a crucial detail for clinicians to consider when choosing a sedative. The implications of this study could be far-reaching, potentially leading to a resurgence of etomidate's use, even in countries where it had been removed from the market. The study's findings may also influence the treatment of patients with conditions like chronic pain, depression, and post-traumatic stress disorder, where ketamine is sometimes used.
And this is the part most people miss... The potential risks of ketamine came to public attention in 2023 when the drug was thought to be a factor in the death of actor Matthew Perry.
The researchers are now investigating the long-term impact of these sedatives on patients. They are evaluating patient-centered outcomes, such as symptoms of post-traumatic stress disorder, at 12 months. They are also conducting further studies, including the INSPIRE trial, to evaluate the use of muscle relaxants during intubation. In addition, VUMC is leading the BREATHE trial, which is studying whether smaller breathing tubes can prevent vocal cord injuries and long-term breathing, speaking, and swallowing problems.
This research underscores the importance of rigorous studies to evaluate existing treatments. As Dr. Casey noted, "Studies like RSI are critically important to understand the treatments that patients are already receiving and to ensure that patients receive the treatments that will result in the best outcomes."
What are your thoughts? Do you think this study will significantly change how emergency airway management is approached? Do you have any personal experiences or insights related to these sedatives? Share your thoughts in the comments below! This research was funded by the Patient-Centered Outcomes Research Institute (grant BPS-2024C1-37478) and the National Institutes of Health (grant K23HL153584).
